KF 72926

Drug Profile

KF 72926

Latest Information Update: 25 Oct 2006

Price : $50

At a glance

  • Originator Kyowa Hakko
  • Class Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Diabetes mellitus

Most Recent Events

  • 25 Oct 2006 Discontinued - Preclinical for Diabetes mellitus in Japan (unspecified route)
  • 01 Dec 2004 Kyowa Hakko exclusively licensed to Sanwa Kagaku Kenkyusho rights to its research and know-how in the field of diabetes
  • 01 Jul 2004 KF 72926 is available for licensing (http://www.kyowa.co.jp/eng/)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top